ASX · CSL.AX
CSL Limited
A$200.15+A$2.65 (+1.34%)
CSL Limited’s quoted price sits in the upper half of its reported 52-week range, 0.98% below the high.
Loading market information…
ASX · NEU.AX · AUD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 04:51 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Neuren Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 14.02% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Neuren Pharmaceuticals Limited’s next earnings report is currently expected on Feb 24, 2027, with estimated earnings per share of A$0.28. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Neuren Pharmaceuticals Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Hawthorn East, Australia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:11 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2023 | Apr 25, 2024 | A$0.83-15.07% vs estimate | A$169.00M+2.24% vs estimate |
|---|
| Q2 2023 | Oct 21, 2023 | A$0.37+14.84% vs estimate | A$62.93M+0.69% vs estimate |
|---|
| Q4 2022 | Feb 24, 2023 | A$0.06 | A$14.55M+4.7% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$200.15+A$2.65 (+1.34%)
CSL Limited’s quoted price sits in the upper half of its reported 52-week range, 0.98% below the high.
A$2.74+A$0.02 (+0.55%)
Sigma Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 14.53% below the high.
A$197.11+A$0.02 (+0.01%)
Pro Medicus Limited’s quoted price sits in the upper half of its reported 52-week range, 27.76% below the high.
A$0.04-A$0.00 (-4.65%)
Actinogen Medical Limited’s quoted price sits in the lower half of its reported 52-week range, 43.06% below the high.
A$0.47-A$0.03 (-5.1%)
Nyrada Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.71% below the high.
A$0.09A$0.00 (0.0%)
Neurizon Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 31.2% below the high.
A$0.26-A$0.00 (0.0%)
Alterity Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 66.88% below the high.
A$0.03+A$0.00 (+3.33%)
Entropy Neurodynamics Limited’s quoted price sits in the lower half of its reported 52-week range, 27.91% below the high.
